共查询到20条相似文献,搜索用时 31 毫秒
1.
Jiaming Lan Yao Deng Hong Chen Guangwen Lu Wen Wang Xiaojuan Guo Zhuozhuang Lu George F. Gao Wenjie Tan 《PloS one》2014,9(11)
The development of an effective vaccine is critical for prevention of a Middle East respiratory syndrome coronavirus (MERS-CoV) pandemic. Some studies have indicated the receptor-binding domain (RBD) protein of MERS-CoV spike (S) is a good candidate antigen for a MERS-CoV subunit vaccine. However, highly purified proteins are typically not inherently immunogenic. We hypothesised that humoral and cell-mediated immunity would be improved with a modification of the vaccination regimen. Therefore, the immunogenicity of a novel MERS-CoV RBD-based subunit vaccine was tested in mice using different adjuvant formulations and delivery routes. Different vaccination regimens were compared in BALB/c mice immunized 3 times intramuscularly (i.m.) with a vaccine containing 10 µg of recombinant MERS-CoV RBD in combination with either aluminium hydroxide (alum) alone, alum and polyriboinosinic acid (poly I:C) or alum and cysteine-phosphate-guanine (CpG) oligodeoxynucleotides (ODN). The immune responses of mice vaccinated with RBD, incomplete Freund’s adjuvant (IFA) and CpG ODN by a subcutaneous (s.c.) route were also investigated. We evaluated the induction of RBD-specific humoral immunity (total IgG and neutralizing antibodies) and cellular immunity (ELISpot assay for IFN-γ spot-forming cells and splenocyte cytokine production). Our findings indicated that the combination of alum and CpG ODN optimized the development of RBD-specific humoral and cellular immunity following subunit vaccination. Interestingly, robust RBD-specific antibody and T-cell responses were induced in mice immunized with the rRBD protein in combination with IFA and CpG ODN, but low level of neutralizing antibodies were elicited. Our data suggest that murine immunity following subunit vaccination can be tailored using adjuvant combinations and delivery routes. The vaccination regimen used in this study is promising and could improve the protection offered by the MERS-CoV subunit vaccine by eliciting effective humoral and cellular immune responses. 相似文献
2.
Lees CJ Apostolopoulos V Acres B Ong CS Popovski V McKenzie IF 《Cancer immunology, immunotherapy : CII》2000,48(11):644-652
MUC1 is a mucin over-expressed in breast cancer and a proposed target for immunotherapy. By immunising mice with MUC1 conjugated
to mannan (M-FP), CD8+ MHC-class-I restricted cytotoxic T lymphocytes (CTL), of high CTL precursor (CTLp) frequency (1/8000) and with significant
tumour protection, can be induced. The effect of various cytokines [interleukin-2 (IL-2), IL-4, IL-6, IL-7, interferon γ (IFNγ),
and granulocyte/macrophage-colony-stimulating factor (GM-CSF)] on the MUC1 CTL immune response was investigated (a) by measuring
the frequencies of CTLp in mice immunised with vaccinia virus constructs containing recombinant cytokines and M-FP, or (b)
by immunising cytokine- or cytokine-receptor-knockout (−/−) mice with M-FP. Vaccinia virus (VV) constructs containing recombinant
cytokines were used either individually or in combination in vivo with M-FP immunisation. M-FP immunisations combined with
VV-IL-2, VV-IL-7 and VV-GM-CSF, and combinations of VV-IFNγ + VV-IL-2, VV-IFNγ + VV-IL-4 or VV-GM-CSF + VV-IL-7 increased
CTLp frequencies up to threefold (1/17 666: M-FP + VV-GM-CSF + VV-IL-7) compared to M-FP (1/77 500) alone. By contrast, M-FP
combined with VV-IL-4 decreased the CTLp frequency threefold whereas VV-IL-6 and VV-IFNγ had no effect. Studies in cytokine-
and cytokine-receptor-gene-knockout (−/−) mice demonstrated that mice that are IL-2 −/− and IL-7 receptor −/− produce the
same CTLp response to M-FP as do control mice, whereas responses in the IL-6 −/−, IL-10 −/− and IFNγ−/− mice were marginally
improved and responses to M-FP in IL-4 −/− and tumour necrosis factor receptor 2 −/− mice were weaker. In spite of the increase
in CTLp frequency, this was not reflected in an in vivo tumour model. Tumour challenges using MUC1+ P815 cells, demonstrated that the addition of cytokines had little additive effect on the already effective tumour-regression
capabilities of M-FP alone.
Received: 24 September 1998 / Accepted: 21 September 1999 相似文献
3.
Junko Shima Takayuki Yoshioka Hiroto Nakajima Hiromi Fujiwara Toshiyuki Hamaoka 《Cancer immunology, immunotherapy : CII》1988,26(1):43-47
Summary A previous paper has demonstrated that enhanced tumor-specific immunity could be induced by priming mice with Bacillus Calmette Guerin (BCG) and subsequently immunizing them with syngeneic tumor cells modified with BCG-cross-reactive muramyl dipeptide (MDP) hapten [15]. The present study establishes a tumorspecific immunotherapy protocol for a murine chronic leukemia based on the above T-T cell collaboration between antitumor effector T cells and anti-MDP hapten helper T cells induced by BCG priming. BALB/c mice which had been primed to BCG were injected intravenously (i.v.) with viable, syngeneic BCL1 leukemia cells. One week later, these mice were immunized intraperitoneally (i.p.) with unmodified or MDP hapten-modified, 10,000 R X-irradiated BCL1 cells, followed by 4 booster immunizations at 5-day intervals. The administration of unmodified BCL1 tumor cells into BCG-primed mice failed to prevent them from tumor death due to the persistent growth of preinjected BCL1 cells. In contrast, the immunization of BCG-primed, BCL1 leukemia-cell-bearing mice with MDP-modified BCL1 cells resulted in a high growth inhibition of leukemia cells and protection of these mice from death by leukemia. It was also revealed that potent tumorspecific, T-cell-mediated immunity was generated in mice which survived in this immunotherapy model. Thus, these results indicate that administration of MDP hapten-modified, syngeneic leukemia cells into leukemia-bearing mice which have been primed with BCG results in potent tumor-specific, T-cell-mediated immunity attributable to preventing the growth of disseminated leukemic cells.This work was supported by a Grant-in-Aid for the Special Project Cancer-Bioscience from the Ministry of Education, Science, and Culture, Japan
Abbreviations used: TATA, tumor-associated transplantation antigens; MDP, muramyl dipeptide; MTP, muramyl tripeptide; BCG, Bacillus Calmette Guerin 相似文献
4.
目的 构建含有Asia-Ⅰ型口蹄疫病毒(FMDV)衣壳蛋白前体P1-2A 基因的真核表达质粒pVAXⅠ-P1-2A,并用pVAXⅠ-P1-2A免疫小鼠,评价其体液免疫和细胞免疫水平。方法 通过RT-PCR 方法扩增得到含有FMDV P1-2A编码区的目的基因,并将其克隆到pMD18-T载体上。将pMD18-T-P1-2A和 pVAXⅠ分别经EcoRⅤ和XbaⅠ双酶切后连接构建真核表达质粒pVAXⅠ-P1-2A。将酶切鉴定正确后的重组质粒转染HeLa细胞进行IFA检测。再进行小鼠血清特异性抗体试验、小鼠T淋巴细胞增殖试验和IFN-γ ELISPOT试验。结果 酶切结果与预期目的条带大小相符;荧光结果表明经pVAXⅠ-P1-2A转染的细胞有明显的黄绿色荧光,说明P1-2A基因在HeLa细胞中得到了表达;小鼠免疫结果表明,用免疫的小鼠都产生了较强的体液免疫和细胞免疫,并且T淋巴细胞增殖数和产生IFN-γ的细胞数和对照组相比显著提高(P<0.05)。间接ELISA试验表明,在免疫第14天抗体水平比对照组明显增高(P<0.05)。结论 成功构建了真核表达质粒pVAXⅠ-P1-2A,并通过小鼠免疫试验发现重组质粒试验组能够诱导产生特异性的体液免疫和细胞免疫应答。 相似文献
5.
A. Yu. Kozlov R. R. Klimova L. N. Shingarova E. F. Boldyreva O. V. Nekrasova S. V. Guryanova T. M. Andronova V. V. Novikov A. A. Kushch 《Molecular Biology》2005,39(3):445-451
The adjuvant activity in DNA immunization against herpes simplex virus type 1 (HSV1) was studied for the granulocyte-macrophage colony-stimulating factor (GM-CSF) synthesized from an eukaryotic expression plasmid (pDNAGM-CSF) and for the synthetic glucosaminyl-muramyl dipeptide (GMDP). A plasmid containing the HSV gD gene (pDNAgD) was used as an immunogen. GMDP and pDNAGM-CSF each enhanced the T-cell immune response to DNA immunization. The protective effect of DNA immunization increased from 63 to 100% when the two plasmids were injected simultaneously and to 96% when pDNAgD was injected one day after injecting GMDP. The results showed that DNA vaccines combined with genetic or peptide adjuvants are promising for DNA immunization against HSV.__________Translated from Molekulyarnaya Biologiya, Vol. 39, No. 3, 2005, pp. 504–512.Original Russian Text Copyright © 2005 by Kozlov, Klimova, Shingarova, Boldyreva, Nekrasova, Guryanova, Andronova, Novikov, Kushch. 相似文献
6.
Dace Skrastina Ivars Petrovskis Ilva Lieknina Janis Bogans Regina Renhofa Velta Ose Andris Dishlers Yuri Dekhtyar Paul Pumpens 《PloS one》2014,9(12)
Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10–20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund''s adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component. 相似文献
7.
Akhmatova NK Semenova IB Donenko FV Kiselevskiĭ MV Kurbatova EA Egorova NB 《Zhurnal mikrobiologii, epidemiologii, i immunobiologii》2006,(6):35-40
Effect of immunomodulators for microbial origin on innate immunity and antitumor system was continued to study. Immunomodificator Immunovac VP-4, purified staphylococcal toxoid and glucosaminyl muramyl dipeptide (GMDP) equally enhanced cytotoxicity of mononuclear leukocytes of peripheral blood of healthy donors. Index of cytotoxicity was 2.78, 2.77 and 2.70 respectively. Reduced metastatic progression of Lewis lung carcinoma in mice was observed after Immunovac VP-4 and GMDP administration. Effectiveness was seen when preparations administered according to schedules including their administration before implantation of the tumor. If preparations were administered number of metastases reduced in 4.4-5.6 times and size of metastases reduced in 7-10 times. Interplay between antitumor activity of studied immunomodulators and cytotoxic activity of NK-cells, which are base effectors of antitumor immune response, are discussed. 相似文献
8.
Protection against lethal subcutaneous challenge of virulent <Emphasis Type="Italic">Y. pestis</Emphasis> strain 141 using an F1-V subunit vaccine
下载免费PDF全文
![点击此处可从《中国科学C辑(英文版)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
In this study, we designed and engineered a two-component recombinant fusion protein antigen as a vaccine candidate against
the possible biological threat of Yersinia pestis. The recombinant F1-V protein was formulated with Alhydrogel. A four-time injection with a dosage of 10, 20 and 50 μg/mouse
in about two months was adopted for vaccination. Serum antibodies and subclass of T helper cells were measured and analyzed.
After the final vaccination, the mice were challenged by 141 strain with 25–600 LD50. In conclusion, the recombinant vaccine was capable of inducing protective immunity against subcutaneous challenge. The level
of serum IgG was supposed to be a main factor that affected the final protection of challenge. 20 μg recombinant protein could
induce an endpoint titre of serum IgG as high as 51200, which was enough to afford 100% protection against 400 LD50 virulent 141 challenge. The antibody isotype analysis showed that the vaccine induced predominantly an IgG1 rather than IgG2a
response. Flow cytometric analysis revealed that Alhydrogel significantly helped induce a stronger humoral immunity instead
of CTL cellular response. These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine. 相似文献
9.
J. Bubeník J. Ježek M. Zaoral J. Hofmann Y. V. Gruntenko J. G. Osipov A. G. Zolotareva T. E. Vakhrusheva V. G. Budker 《Cancer immunology, immunotherapy : CII》1984,18(2):123-125
Summary Treatment with synthetic MDP inhibited growth of transplantable, chemically induced tumors in syngeneic mice. The tumor-inhibitory effect was dependent on the schedule of MDP administration.Growth of SC transplants of a nonmetastasizing, MC-induced fibrosarcoma, MC11, was inhibited by local treatment with 200 g and 1,000 g MDP given SC 5–7 weeks before challenge. Treatment with lower (10 g and 100 g) doses of MDP and shorter (1–4 weeks) time intervals was not effective. Single doses of MDP (10–1,000 g) 1–3 weeks after challenge had no effect.Growth of IV-inoculated, metastasizing AAT-induced hepatoma A was inhibited by IV injections of 20 g MDP given 1 and 2 days prior to the challenge. Significant increases in the survival of hepatoma-bearing mice were observed only after injections of MDP incorporated in multilamellar liposomes.Abbreviations MDP
n-acetylmuramyl-l-alanyl-d-isoglutamine
- B10
C57BL/10ScSnPh mice
- MC
3-methylcholanthrene
- ATT
o-amino-azotoluene
- PBS
phosphate-buffered saline 相似文献
10.
A L Rakhmilevich M S Rakhimova 《Biulleten' eksperimental'no? biologii i meditsiny》1989,108(12):721-724
The intratumoral administration of lipopolysaccharide (LPS) and muramyl dipeptide (MDP) in combination, but not separately, resulted in necrosis and rejection of subcutaneous P815 mastocytoma nodules in DBA/2 mice with 30 to 40% survival. Previous sensibilization of animals by LPS + MDP, treatment by indomethacin, cyclophosphamide or syngeneic lymphocytes did not augment the immunotherapeutic action of LPS + MDP combination. Reinoculation of P815 cells into cured DBA/2 mice 8 months after the disappearance of the primary tumor led to rejection of new nodules with 50% survival rate. In LPS + MDP immunotherapy of these tumors two stages may be distinguished by a thrombo-necrotic stage and that of development of immunity. 相似文献
11.
Haimovich J Kukulansky T Weissman B Hollander N 《Cancer immunology, immunotherapy : CII》1999,47(6):330-336
Idiotypic determinants of immunoglobulins of malignant B lymphocytes and plasma cells are tumor-specific antigens and have
been used extensively in immunotherapy studies. The mechanisms involved in resistance to tumor challenge following idiotype
vaccination are poorly understood. Although a predominant role has been attributed to anti-idiotype antibodies, both humoral
and cellular immune responses are probably involved. Cell-mediated responses may be particularly effective against tumor cell
variants that do not express the idiotype on the cell surface and are therefore resistant to anti-idiotype antibodies but
continue to produce one of the original immunoglobulin polypeptides that may be processed and presented to T cells. In this
report we describe two experimental models of idiotype vaccination in which antibodies are unlikely to play a role, and hence
tumor immunity is attributed to cell-mediated responses. One model consists of the murine B lymphocyte tumor 38C-13 and its
idiotype-negative variant DB2, which has lost the idiotypic specificity of the parental 38C-13 cell line through the production
of a different light chain but expresses the original heavy chain. Vaccination of mice with the purified IgM of 38C-13 induced
resistance to 38C-13 tumor cells as well as to the variant cells. Although immunized mice produced high levels of anti-idiotype
antibodies that bound to 38C-13 cells, no binding of antibodies to DB2 cells occurred. The finding that idiotype-vaccinated
mice were resistant to idiotype-negative DB2 cells suggested that cellular mechanisms are involved in mediating resistance.
The second model consists of the two plasma cell line JLμs and JLμm, which produce IgM with an identical specificity. Whereas
one of them (JLμs) secretes the IgM, the other one(JLμm) can neither secrete nor deposit it on the cell surface. Immunization
against JLμs IgM followed by tumor challenge resulted in prolonged survival of both JLμs- and JLμm-challenged mice. Although
sera of immunized mice contained high levels of anti-idiotype antibodies, they did not react with the plasmacytoma cells.
Similarly to the results obtained in the 38C-13 experimental model, these results suggest that a non-antibody-mediated mechanism
was involved in the resistance of mice to tumor growth.
Received: 11 June 1998 / Accepted: 26 November 1998 相似文献
12.
A. G. Laman A. O. Shepelyakovskaya Kh. M. Boziev G. V. Savinov F. A. Brovko V. A. Nesmeyanov 《Russian Journal of Bioorganic Chemistry》2010,36(2):157-163
A method for the preparation of peptide mimetics of GMDP which could exhibit adjuvant activity without the negative effects
of GMDP is described. The search for peptides with GMDP-like adjuvant activity was performed using highly specific monoclonal
antibodies against GMDP and combinatorial peptide libraries in the format of phage display. Various elution methods were used
for the immunoaffinity enrichment of the libraries during the course of the preparation of highly active and specific peptides.
A sole peptide Arg-Val-Pro-Pro-Arg-Tyr-His-Ala-Lys-Ile-Ser-Pro-Met-Val-Asn (RN) was obtained by the elution of phage particles
from the immunosorbent with a 1 μM solution of the natural ligand (GMDP). Elution with a buffer with a low pH value (0.1 M
glycine-HCl, pH 2.2) gave two other peptides: Ser-Gly-Arg-Val-Ala-Val-Ser-Pro-Asp-Ser-Pro-Leu-Phe-Tyr-Pro (SP) and Arg-Tyr-Gly-Gly-Ser-Val-Leu-Asn-Ile-Glu-Cys-Gln-Phe-Tyr-Gly
(RG). Affinity constants for the RN and SP peptides proved to be 3.6 × 108 and 3.5 × 108 M−1, respectively. The specificity of the interaction with the monoclonal antibodies was checked by the competitive displacement
of the peptides from the antigen-antibody complex by GMDP. The RN peptide exhibited adjuvant activity similar to that of GMDP,
but had no pyrogenic effect characteristic of GMDP. The described method could be used for the search for mimetics of biologically
active low-molecular compounds. 相似文献
13.
Alessandra Cesano Sophie Visonneau John H. Wolfe K. Ann Jeglum Jose Fernandez Alfred Gillio Richard J. O’Reilly D. Santoli 《Cancer immunology, immunotherapy : CII》1997,44(3):125-136
The human MHC-non-restricted cytotoxic T cell line TALL-104 has been shown to display potent antitumor effects in several
animal models with spontaneous and induced malignancies. In view of its potential future use in cancer therapy, we investigated
the tolerability and target-organ toxicity of these cells in various animal species. The acute toxicity of TALL-104 cell administrations
was evaluated in: (a) healthy immunocompetent mice and immunodeficient (SCID) mice bearing human tumors using multiple (up
to 15) intraperitoneal (i.p.) injections, and (b) healthy dogs, tumor-bearing dogs, and healthy monkeys using multiple (up
to 17) intravenous (i.v.) injections. TALL-104 cells were γ-irradiated (40 Gy) prior to administration to mice and dogs, but
administered without irradiation in monkeys. Cell doses ranged from 5×107/kg to 1010/kg for each injection. All regimens were well tolerated, the main clinical signs observed being transient gastrointestinal
effects. Moderate and transient increases in liver transaminase levels were observed in all animal species. Discrete and transient
leukocytosis with neutrophilia was also noted in dogs and monkeys after i.v injections of TALL-104 cells. Histological analysis
revealed foci of hepatic necrosis with lympho-/mono-/granulocytic infiltration in immunocompetent mice injected i.p. with
5×109 – 1010 cells/kg. In the same mice, the colon showed an increased number of muciparous cells and alterations in the villi structure:
these alterations were completely reversed by 72 h after the last injection, while liver alterations reversed more slowly
(1 week). No delayed or chronic toxicity was observed in any of the animals even when non-irradiated TALL-104 cells were administered:
both immunocompetent mice and healthy dogs were found to be grossly and histopathologically normal when sacrificed (1 year
and 1 month after the last TALL-104 injection respectively). TALL-104 cells did not persist in these hosts. In addition, monkeys
showed no molecular signs of TALL-104-cell-induced leukemia in their blood 1 year after the last cell injection. Despite immunosuppression,
most of the tumor-bearing dogs as well as the healthy dogs and monkeys developed both humoral and cellular immune responses
against TALL-104 cells. The data derived from these preclinical studies suggest that administration of high doses of irradiated
TALL-104 cells is well tolerated and would be unlikely to induce severe toxicity if applied in clinical trials to the treatment
of patients with refractory cancer.
Received: 8 September 1996 / Accepted: 28 January 1997 相似文献
14.
Marni E. Cueno Yurina Hibi Katsuo Karamatsu Yasuhiro Yasutomi Kenichi Imai Antonio C. Laurena Takashi Okamoto 《Transgenic research》2010,19(5):889-895
HIV-1 Tat plays a major role in viral replication and is essential for AIDS development making it an ideal vaccine target
providing that both humoral and cellular immune responses are induced. Plant-based antigen production, due to its cheaper
cost, appears ideal for vaccine production. In this study, we created a plant-optimized tat and mutant (Cys30Ala/Lys41Ala) tat (mtat) gene and ligated each into a pBI121 expression vector with a stop codon and a gusA gene positioned immediately downstream. The vector construct was bombarded into tomato leaf calli and allowed to develop.
We thus generated recombinant tomato plants preferentially expressing a Tat-GUS fusion protein over a Tat-only protein. In
addition, plants bombarded with either tat or mtat genes showed no phenotypic difference and produced 2–4 μg Tat-GUS fusion protein per milligram soluble plant protein. Furthermore,
tomato extracts intradermally inoculated into mice were found to induce a humoral and, most importantly, cellular immunity. 相似文献
15.
MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines 总被引:12,自引:0,他引:12
Acres B Apostolopoulos V Balloul JM Wreschner D Xing PX Ali-Hadji D Bizouarne N Kieny MP McKenzie IF 《Cancer immunology, immunotherapy : CII》2000,48(10):588-594
Analyses of MUC1-specific cytotoxic T cell precursor (CTLp) frequencies were performed in mice immunized with three different
MUC1 vaccine immunotherapeutic agents. Mice were immunized with either a fusion protein comprising MUC1 and glutathione S-transferase (MUC1-GST), MUC1-GST fusion protein coupled to mannan (MFP) or with a recombinant vaccinia virus expressing both
MUC1 and interleukin-2. Mouse strain variations in immune responsiveness have been observed with these vaccines. We have constructed
mice transgenic for the human MUC1 gene to study MUC1-specific immune responses and the risk of auto-immunity following MUC1 immunization. Transgenic mice immunized
with MUC1 were observed to be partially tolerant in that the MUC1-specific antibody response is lower than that observed in
syngeneic but non-transgenic mice. However, a significant MUC1-specific CTLp response to all three vaccines was observed,
indicating the ability to overcome T cell, but to a lesser extent B cell, tolerance to MUC1 in these mice. Histological analysis
indicates no evidence of auto-immunity to the cells expressing the human MUC1 molecule. These results suggest that it is possible
to generate an immune response to a cancer-related antigen without damage to normal tissues expressing the antigen.
Received: 7 July 1999 / Accepted: 26 August 1999 相似文献
16.
The morbidity and mortality of infectious diseases are significantly increased in aged humans. Hence, vaccination has been suggested as a means to reduce or prevent the impact of infections on old individuals. However, it has remained unresolved whether or not standard vaccine adjuvants such as aluminum hydroxide (Alum) are similarly efficacious in old individuals, as compared to young adults. Here, we have investigated the effects of prototypic immunological adjuvants, complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA), or Alum on HEL-specific T cell responses in young adult and old mice. We report that independent of the adjuvant used, the induced T cell responses to the prototypic protein antigen hen eggwhite lysozyme (HEL) were similar in young adult and old mice in terms of cytokine production, T cell frequencies, determinant specificity, and T cell repertoire. The results suggest that vaccine adjuvants developed in young adults should be equally effective in inducing T cell immunity in old individuals. 相似文献
17.
将我国分离的首株人H5N1亚型禽流感病毒A/Anhui/1/2005作为研究对象,扩增其HA和HA1基因片段并克隆至真核表达载体pStar,构建成真核表达质粒。通过Western blot和间接免疫荧光检测方法确认,构建的重组质粒在真核细胞中成功地表达了目的蛋白HA和HA1。将重组质粒免疫BALB/c小鼠,检测免疫后外周血中HA/HA1特异性抗体的效价,并比较HA和HA1的免疫原性。结果表明,重组质粒免疫后成功地诱导了体液免疫反应,且二者的血清抗体效价无显著性差异。 相似文献
18.
Yao Deng Jie Guan Bo Wen Na Zhu Hong Chen Jindong Song Yang Yang Yue Wang Wenjie Tan 《PloS one》2013,8(4)
Introduction
Integration-deficient lentiviral vectors (IDLVs) are a promising platform for immunisation to elicit both humoral immunity and cellular mediated immunity (CMI). Here, we compared the specific immunity in mice immunised via different regimens (homologous and cocktail) with IDLV-based HCV pseudoparticles (HCVpps) carrying pseudotyped glycoproteins E1E2 and bearing the HCV NS3 gene. Humoral and cell-mediated immune responses were also evaluated after IDLV-HCVpp immunisation combined with heterologous rAd5-CE1E2 priming protocols. Sera from the mice effectively elicited anti-E1, -E2, and -NS3 antibody responses, and neutralised various HCVpp subtypes (1a, 1b, 2a, 3a and 5a). No significant CMI was detected in the groups immunised with IDLV-based HCVpps. In contrast, the combination of rAd5-CE1E2 priming and IDLV-based HCVpp boosting induced significant CMI against multiple antigens (E1, E2, and NS3).Conclusion
IDLV-based HCVpps are a promising vaccination platform and the combination of rAd5-CE1E2 and IDLV-based HCVpp prime-boost strategy should be further explored for the development of a cross-protective HCV vaccine. 相似文献19.
Matsumoto S Matsumoto M Umemori K Ozeki Y Furugen M Tatsuo T Hirayama Y Yamamoto S Yamada T Kobayashi K 《Journal of immunology (Baltimore, Md. : 1950)》2005,175(1):441-449
Mycobacterium consists up to 7% of mycobacterial DNA-binding protein 1 (MDP1) in total cellular proteins. Host immune responses to MDP1 were studied in mice to explore the antigenic properties of this protein. Anti-MDP1 IgG was produced after infection with either bacillus Calmette-Guérin or Mycobacterium tuberculosis in C3H/HeJ mice. However, the level of Ab was remarkably low when purified MDP1 was injected. MDP1 is considered to be associated with DNA in nucleoid, which contains immunostimulatory CpG motif. Therefore, we examined coadministration of MDP1 and DNA derived from M. tuberculosis. Consequently, this procedure significantly enhanced the production of MDP1-specific IgG. Five nanograms of DNA was enough to enhance MDP1-specific IgG production in the administration of 5 microg of MDP1 into mice. Strong immune stimulation by such a small amount of DNA is noteworthy, because >1,000- to 100,000-fold doses of CpG DNAs are used for immune activation. A synthetic peptide-based study showed that B cell epitopes were different between mice administered MDP1 alone and those given a mixture of MDP1 and DNA, suggesting that DNA alters the three-dimensional structure of MDP1. Coadministration of DNA also enhanced MDP1-specific IFN-gamma production and reduced the bacterial burden of a following challenge of M. tuberculosis, showing that MDP1 is a novel vaccine target. Finally, we found that MDP1 remarkably enhanced TLR9-dependent immune stimulation by unmethylated CpG oligo DNA in vitro. To our knowledge, MDP1 is the first protein discovered that remarkably augments the CpG-mediated immune response and is a potential adjuvant for CpG DNA-based immune therapies. 相似文献
20.
O. V. Masalova E. I. Lesnova A. A. Onishchuk A. M. Ivanova E. V. Gerasimova A. V. Ivanov A. N. Narovlyansky A. V. Sanin A. V. Pronin A. A. Kushch 《Doklady. Biochemistry and biophysics》2018,482(1):261-263
The search for new adjuvants remains the critical task for the creation of hepatitis C vaccines due to the weak immunogenicity of biotechnological products. When immunizing mice with the recombinant proteins NS3 and NS5B of the hepatitis C virus (HCV), the adjuvant activity of three immunomodulators was compared. Phosprenyl® on the basis of polyprenyl phosphate (PPP), chemically synthesized analogue of the bacterial cell wall glucosaminyl muramyl dipeptide (GMDP), and IFN-α recombinant protein were tested. GMDP increased the activity of IgG1 antibodies 4–6 times but did not stimulate the production of IFN-γ; IFN-α has not shown any adjuvant properties. The introduction of recombinant HCV proteins together with PPP in low doses increased the activity of IgG2a isotype antibodies 4–7 times and increased IFN-γ secretion 3 times. Thus, it was first shown that PPP polarizes the immune response to Th1-type and is a promising adjuvant for the development of a vaccine against hepatitis C. 相似文献